TYK2 inhibition: changing the treatment landscape for psoriasis?
- 23 November 2021
- journal article
- editorial
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 18 (3) , 185-187
Abstract
Psoriasis is a common immune-mediated inflammatory disease affecting approximately 2% of individuals living in Western countries. Patients with psoriasis suffer from a multitude of comorbidities su...Keywords
This publication has 6 references indexed in Scilit:
- Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domainScience Translational Medicine, 2019
- Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165Journal of Medicinal Chemistry, 2019
- Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in PsoriasisNew England Journal of Medicine, 2018
- Psoriasis pathogenesis and the development of novel targeted immune therapiesJournal of Allergy and Clinical Immunology, 2017
- PsoriasisThe Lancet, 2015
- Human Tyrosine Kinase 2 Deficiency Reveals Its Requisite Roles in Multiple Cytokine Signals Involved in Innate and Acquired ImmunityImmunity, 2006